Metaberine^™

Metaberine™ is an advanced, clinically proven Berberine ingredient formulated with proprietary BioSOLVE® technology, a 100% aqueous, green manufacturing process that converts standard Berberine into a highly porous, water-soluble powder for dramatically improved absorption. It supports metabolic health by activating the AMPK enzyme, often called the body’s “metabolic master switch,” which helps regulate energy production, glucose uptake, and fat metabolism at the cellular level. Metaberine™ also improves insulin sensitivity and supports healthy GLP-1 secretion, the hormone pathway responsible for appetite regulation and blood sugar control. In clinical testing, these mechanisms combined to deliver a 23% increase in GLP-1 secretion, an 8% reduction in fasting blood glucose, and a 14% decrease in post-prandial glucose spikes, at a daily dose of just 200 mg, far below the 500-1500 mg typically required with standard Berberine extracts.

Yes. Metaberine™ supports weight management through multiple, clinically validated mechanisms rather than a single pathway. It activates the AMPK enzyme to enhance fat metabolism and improve how efficiently the body burns stored energy. It also boosts GLP-1 secretion by 23% in clinical testing, a hormone pathway that regulates appetite and satiety, which helps reduce cravings and supports more consistent eating patterns. Additionally, Metaberine™ improves insulin sensitivity, helping the body use glucose for energy rather than storing it as fat, and contributed to an 8% reduction in fasting blood glucose and a 14% decrease in post-prandial glucose spikes in trial participants. Because Metaberine™ achieves these effects at just 200 mg per day, roughly one-third to one-eighth the dose required by standard Berberine extracts, it offers a more efficient, better-tolerated option for brands formulating weight management and metabolic health products.

Yes, Metaberine™ is well suited for supporting individuals managing PCOS (polycystic ovary syndrome) or broader metabolic syndrome, both of which are closely linked to insulin resistance. Metaberine™ improves insulin sensitivity by activating the AMPK enzyme and supporting healthier glucose metabolism, addressing one of the root physiological drivers of PCOS symptoms. In clinical testing, Metaberine™ was associated with an 8% reduction in fasting blood glucose and a 14% decrease in post-prandial glucose spikes, both relevant markers for individuals with insulin resistance. Improved insulin response also supports better hormonal balance, since insulin resistance is a key contributor to the hormonal imbalances seen in PCOS. Metaberine™ delivers these benefits at a low 200 mg daily dose thanks to its 15× higher bioavailability compared to standard Berberine, making it a practical, well-tolerated ingredient for formulations targeting metabolic and hormonal health.

Metaberine™ improves insulin sensitivity and blood sugar control by activating two complementary metabolic pathways: AMPK, which regulates cellular energy use and glucose uptake, and GLP-1, the hormone pathway that supports insulin release and appetite regulation. Activating both pathways together helps the body process glucose more efficiently at the cellular level. In a randomised, double-blind, placebo-controlled crossover trial, this dual-pathway activation produced measurable clinical outcomes: a 23% increase in GLP-1 secretion, an 8% reduction in fasting blood glucose, and a 14% decrease in post-prandial glucose spikes after meals. These results were achieved using Metaberine™’s BioSOLVE®-enhanced form, which delivers 15× higher bioavailability and 10× higher peak plasma concentration than standard Berberine powder, reaching peak concentration in about 2.3 hours versus 4 hours for the conventional form, allowing effective blood sugar support at a low 200 mg daily dose.

Standard Berberine extract suffers from poor oral bioavailability, typically under 2% absorption, meaning the vast majority of a dose passes through the body unused, which is why conventional products require high doses of 500-1500 mg per day and often cause gastric discomfort. Metaberine™ solves this through proprietary BioSOLVE® technology, a 100% aqueous, green manufacturing process that restructures Berberine into a highly porous, water-soluble powder. In head-to-head clinical testing, this gave Metaberine™ 15× higher bioavailability and 10× higher peak plasma concentration (Cmax) than standard Berberine powder, while reaching peak concentration in about 2.3 hours versus 4 hours for the conventional form. As a result, Metaberine™ delivers clinically proven metabolic benefits, including a 23% increase in GLP-1 secretion, at a far lower 200 mg daily dose, with no reported gastric irritation.

Yes. Metaberine™ has been pharmacokinetically tested in a randomised, double-blind, placebo-controlled crossover trial and is manufactured in a GMP-certified, USFDA-registered facility aligned with ISO 9001:2015 and ISO 22000:2018 standards. At its clinically effective dose of 200 mg per day, Metaberine™ was well tolerated with no reported gastric irritation, directly addressing the most common side effect associated with high-dose conventional Berberine supplements, which typically require 500-1500 mg per day to achieve similar effects. This improved tolerability comes from Metaberine™’s proprietary BioSOLVE® technology, which increases bioavailability 9-fold and allows the ingredient to work effectively at a fraction of the standard dose. The combination of clinical validation, third-party manufacturing certifications, and a strong tolerability profile makes Metaberine™ a safe option for daily use in metabolic health and weight management formulations.

Metaberine® doesn’t just improve Berberine’s absorption, it offers a more practical alternative to liposomal Berberine for brands formulating metabolic health products. Liposomal delivery systems can improve absorption, but they introduce formulation challenges, including stability issues over shelf life, difficulty maintaining a consistent lipid-to-active ratio, and inconsistent uniformity and flowability during manufacturing. Metaberine™ instead uses proprietary BioSOLVE® technology, a 100% aqueous, green manufacturing process that restructures Berberine into a highly porous, water-soluble powder, delivering 15× higher bioavailability and 10× higher peak plasma concentration than standard Berberine, without the manufacturing complexity of lipid-based systems. This makes Metaberine™ a clinically validated, cost-effective, and formulation-friendly solution: it behaves like a standard powder ingredient during manufacturing while still delivering the absorption benefits brands typically seek from liposomal alternatives, at a low 200 mg daily dose.